Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy
Front Oncol
.
2023 Jul 25:13:1257622.
doi: 10.3389/fonc.2023.1257622.
eCollection 2023.
Authors
Victoria M Valvo
1
2
,
Emanuele Vitale
3
4
,
Marco Tigano
4
,
Rachel Evans
5
6
,
Meredith A Morgan
1
,
Qiang Zhang
1
Affiliations
1
Department of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States.
2
Cancer Biology Program, University of Michigan, Ann Arbor, MI, United States.
3
Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
4
MitoCare Center, Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA, United States.
5
Richard Dimbleby Department of Cancer Research, Randall Division & Division of Cancer Studies, Kings College London, London, United Kingdom.
6
Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
PMID:
37560464
PMCID:
PMC10408123
DOI:
10.3389/fonc.2023.1257622
No abstract available
Keywords:
DNA damage response; immunotherapy; innate immunity; radiotherapy; tumor microenvironment.
Publication types
Editorial
Grants and funding
R01 CA240515/CA/NCI NIH HHS/United States